In R Foundation for Statistical Computing.

Vienna, Austria; 2008. 88. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al.: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80.PubMedCrossRef 89. Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG: BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 2008, 24:2921–2922.PubMedCrossRef 90. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004., 3: Article 3 91. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B 1995, 57:289–300. 92. Saeed AI, Sharov V, White J, Li

J, Liang W, Bhagabati N, et al.: TM4: a free, open-source system for microarray this website data management and analysis. Biotechniques 2003, 34:374–378.PubMed 93. Draghici S, Khatri P, Bhavsar P, Shah A, Krawetz SA, Tainsky MA: Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Res 2003, 31:3775–3781.PubMedCrossRef 94. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, et al.: A systems biology approach for pathway level analysis. Genome Res 2007, 17:1537–1545.PubMedCrossRef 95. Khatri P, Sellamuthu S, Malhotra P, Amin K, Done A, Draghici S: Recent additions and improvements to the Onto-Tools. Nucleic Acids Res 2005, 33:W762-W765.PubMedCrossRef Authors’ contributions LLE, YE and TMT performed inoculation and co-incubation of cells and bacteria, Wnt inhibitor as well as performed ELISA and rt-PCR analysis. YE Sirolimus solubility dmso and TMT carried out immunofluorescence and microscopy. IRKB participated in the design of the study, and GB coordinated the study and helped to draft the manuscript. LLE carried out the microarray data analysis and wrote the main manuscript. All authors read and approved the final manuscript.”
“Background Urinary tract infections (UTIs) are a universal source of human morbidity, with millions of cystitis

and pyelonephritis episodes reported annually [1]. An estimated 40-50% of all women will experience at least one UTI in their lifetime, and one in three women will have had at least one clinically diagnosed UTI by the age of 24 [2]. Direct health care costs due to UTI exceed $1 billion each year in the USA alone [2]. Staphylococcus saprophyticus, a coagulase-negative staphylococcus, is the second most common causative agent of community-acquired urinary tract infection after Escherichia coli [3], and is responsible for up to 20% of cases. S. saprophyticus is of particular significance to sexually active young women, accounting for over 40% of UTI in this demographic [4]. S. saprophyticus UTI symptoms mirror those of E. coli [5] and recurrence is common, affecting 10-15% of infected women [6].